Corticosteroid (long acting)
Short-term management of inflammatory and allergic disorders, such as
rheumatoid arthritis, collagen diseases (eg SLE), dermatologic diseases (eg
pemphigus), status asthmaticus, and autoimmune disorders
Use cautiously with kidney or liver disease, hypothyroidism, ulcerative colitis
with impending perforation, diverticulitis, active or latent peptic ulcer,
inflammatory bowel disease, CHF, hypertension, thromboembolic disorders,
osteoporosis, seizure disorders, diabetes mellitus.
Tablets\u20140.6 mg; syrup\u20140.6 mg/5 mL; injection\u20144 mg, 3 mg betamethasone sodium phosphate with 3 mg betamethasone acetate; ointment\u20140.1%, 0.05%; cream\u20140.01%, 0.05%, 0.1%; lotion\u20140.1%, 0.05%; gel\u20140.05%
Individualize dosage, based on severity and response. Give daily dose before 9 AM to minimize adrenal suppression. Reduce initial dose in small increments until the lowest dose that maintains satisfactory clinical response is reached. If long-term therapy is needed, alternate-day therapy with a short-acting corticosteroid should be considered. After long-term therapy, withdraw drug slowly to prevent adrenal insufficiency.
Individualize dosage on the basis of severity and response rather than by formulae that
correct adult doses for age or weight. Carefully observe growth and development in
infants and children on prolonged therapy.
Metabolism: Hepatic; T1/2: 36\u201354 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Unchanged in the urine
carbohydrate tolerance, diabetes mellitus, cushingoid state (long-term effect),
increased blood sugar, increased serum cholesterol, decreased T3 and T4 levels,
hypothalamic-pituitary-adrenal (HPA) suppression with systemic therapy longer
than 5 days
This action might not be possible to undo. Are you sure you want to continue?